Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) EBITDA (2016 - 2025)

Historic EBITDA for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $323.0 million.

  • Dexcom's EBITDA rose 7098.99% to $323.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $911.8 million, marking a year-over-year increase of 5196.67%. This contributed to the annual value of $911.8 million for FY2025, which is 5196.67% up from last year.
  • Per Dexcom's latest filing, its EBITDA stood at $323.0 million for Q4 2025, which was up 7098.99% from $242.5 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's EBITDA registered a high of $323.0 million during Q4 2025, and its lowest value of $600000.0 during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was $130.9 million (2023), whereas its average is $138.3 million.
  • As far as peak fluctuations go, Dexcom's EBITDA plummeted by 9942.31% in 2021, and later surged by 2080000.0% in 2022.
  • Quarter analysis of 5 years shows Dexcom's EBITDA stood at $600000.0 in 2021, then surged by 20800.0% to $125.4 million in 2022, then surged by 72.97% to $216.9 million in 2023, then dropped by 12.91% to $188.9 million in 2024, then soared by 70.99% to $323.0 million in 2025.
  • Its EBITDA was $323.0 million in Q4 2025, compared to $242.5 million in Q3 2025 and $212.6 million in Q2 2025.